Kornimate/medical-research-clean huggingface dataset:
temporomandibular disorders among patients with tinnitus

Conditions: Tinnitus; Temporomandibular Disorder

Summary: the incidence of temporomandibular disorders will be studied among patients with tinnitus, by the use of patient's history and physical examination.

the patients with tinnituswill be asked about symptoms related to temporomandibular disorders, and also will be examined in order to diagnose such disorders.

Eligibility criteria:
inclusion criteria: * tinnitus lasting more than 3 months exclusion criteria: * head and neck space occupying lesion * previous degenerative disease of the temporomandibular koint
prediction of antidepressant response using pharmacogenetics and peripheral lymphocytic phenotype

Conditions: Depression

Summary: the purpose of this study is to determine whether pharmacogenomic study of bioamine transporters and peripheral lymphatic biomarkers(phenotype) predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.

the purpose of this study is to determine whether genomic effects or peripheral lymphatic biomarkers on antidepressant response differed by class of drug, whether genomic and biomarker differences between drug responders and nonresponders predict the response of antidepressant and to construct the prediction model for antidepressant treatment in order to aid to select the their genetically or endophenotypic matching drugs.

Eligibility criteria:
inclusion criteria: 1. eligible patients were enrolled in the clinical trials program of hte samsung medical center geropsychiatry and affective disorder clinics(seoul, korea). they received a semistructured diagnostic interview, the samsung psychiatric evaluation schedule. the affective disorder section of the samsung psychiatric evaluation schedule uses the korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, fourth edition. 2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians exclusion criteria: 1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant axis i psychiatric disorder.

Keywords: pharmacogenomics prediction of antidepressant response depressed patients biomarkers phenotype antidepressant response adverse reaction to drug
pemetrexed in advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the ≥ second line setting in a large cohort of advanced non-small cell lung cancer (nsclc) patients. the following biomarkers will be investigated with either immunohistochemistry, fluorescence in situ hybridization or genotyping: thymidylate synthase (ts), dihydrofolate reductase (dhfr), glycinamide ribonucleotide formyl transferase (garft), aminoimidazole carboxamide ribonucleotide formyltransferase (atic/aicarft), epidermal growth factor receptor (egfr), kirsten rat sarcoma 2 viral oncogene homolog (kras), v-myc myelocytomatosis viral oncogene homolog (myc) and phosphoinositide-3-kinase, catalytic, alpha polypeptide (pik3ca).


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of advanced non-small cell lung cancer - tumor tissue available at our institution * patients treated with single agent pemetrexed for metastatic disease * availability of full clinical data exclusion criteria: * cytological diagnosis of advanced non-small cell lung cancer * lack of tumor tissue at our institution * lack of full clinical data
resolution of pain and swelling after the use of neem leaf extract compared to chlorhexidine gluconate as an intracanal irrigant during pulpectomy

Conditions: Periapical Abscess

Summary: the trial is to test the resolution of pain, swelling and other signs of periapical infection and the antimicrobial efficacy when using the neem leaf extract compared to chlorhexidine as root canal irrigant in pulpectomy treatment for children.

to compare the effectiveness of neem leaf extract with that of chlorhexidine gluconate when used as an intracanal irrigant in primary molar teeth indicated for pulpectomy treatment. p: children with primary necrotic molars indicated for pulpectomy i: neem leaf extract (alcoholic solution). c: 2% chlorhexidine gluconate. o: pain and swelling resolution. t:over 12 months. s: randomised controlled trial.

Eligibility criteria:
inclusion criteria: * patient and parent cooperation. * absence of any systemic disease that would contraindicate pulp therapy. * non vital molar teeth presenting with an acute or chronic periapical infection as a result of pulp necrosis ( periapical abscess ,a sinus tract formation as a sequelae ) * making sure the patient is not taking an antibiotic and has not taken it for the past 2 weeks. * absence of physiologic or pathologic root resorption that contraindicate pulp therapy. * restorable teeth * molars with at least two thirds of root remaining. exclusion criteria: * children with any condition that contraindicates pulp therapy will be excluded (rheumatic fever, infective endocarditis , leukemia , corticosteroid therapy and immunosuppressed children).
reducing respiratory virus transmission in bangladeshi classrooms

Conditions: SARS-CoV2 Infection; Influenza Viral Infections; Respiratory Viral Infection

Summary: this study will test if affordable air cleaning devices (box fans with a filter attached and/or ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience.

this cluster-randomized controlled trial in bangladesh schools will examine whether low-cost air filtration and/or human-safe ultraviolet germicidal light interventions can reduce the incidence of schoolchildren's respiratory viral infections. the main study objectives are: 1. pilot and optimize an intervention to filter classroom air. 2. pilot and optimize an intervention to treat classroom air with ultraviolet light. 3. assess the separate and combined effect of air filtration and ultraviolet light on the incidence of polymerase chain reaction (pcr) confirmed illness from respiratory viruses. methods: the study will take place in 60 government primary schools in dhaka, bangladesh. within each enrolled school, 5 classrooms of students in grades 3, 4 and 5 will be randomly assigned to receive: 1. box fans with a filter attachment. 2. 220 nanometer (nm) wavelength ultraviolet light air cleaner lamps. 3. both the box fans with a filter and the 220 nm ultraviolet lamps. 4. no device: a control group that receives no additional device ("standard of care"). two classrooms within each school will be assigned as controls. why does this matter?: clarifying the impact of low-cost practical solutions could support the adoption of these strategies that could reduce influenza and severe acute respiratory syndrome coronavirus 2 (sars-cov-2) transmission in schools in order to reduce the burden of respiratory illness in these communities.

Eligibility criteria:
inclusion criteria: * schoolchildren of bangladesh government-run primary schools in dhaka, bangladesh ages 9 - 12 years, of all gender identifiers (male, female, transgender, prefer not to designate), without specific ethnic selection amongst standard school children of bangladesh government schools in dhaka, bangladesh. exclusion criteria: * school children of non-bangladesh government-run primary schools and/or schoolchildren who do not attend a bangladesh government-run primary school in dhaka, bangladesh. * school children who are not able to or have a contraindication with the ability to comply with study procedures.

Keywords: bangladesh indoor air quality air cleaning respiratory viral infections influenza sars-cov2 air filtration ultraviolet germicidal irradiation global health
the effect of diabetes mellitus on mortality of patients with covid-19

Conditions: Covid19; Diabetes Mellitus

Summary: the study includes patients over 18 years old who were hospitalized in our covid intensive care unit between march 16 and may 16, 2020. retrospective records were examined by examining the electronic data files of the patients. polymerase chain reaction (pcr) tests performed with nasopharyngeal swab taken from the person, which is the standard diagnostic method, and also the diagnosis of infection symptoms, risk factors and thoracic ct scans indicating pneumonia were diagnosed. patients over 18 years of age with and without a medical history of dm in their history were identified and compared in 2 groups.

the study includes patients over 18 years old who were hospitalized in our covid intensive care unit between march 16 and may 16, 2020. retrospective records will be examined by examining the electronic data files of the patients. polymerase chain reaction (pcr) tests performed with nasopharyngeal swab taken from the person, which is the standard diagnostic method, and also the diagnosis of infection symptoms, risk factors and thoracic ct scans indicating pneumonia were diagnosed. patients over 18 years of age with and without a medical history of dm in their history will be identified and compared in 2 groups. demographic data such as age, gender, body mass index (bmi) of all patients, presence of additional comorbid disease, blood glucose values during hospitalization in intensive care, ferritin, c-reactive protein (crp), respiratory support methods (nasal oxygen, nasal high flow, non-invasive mechanical ventilation, intubation), length of stay in intensive care unit, and mortality will be recorded.

Eligibility criteria:
inclusion criteria: * all patients over 18 years of age exclusion criteria: * patients under 18 years of age
bioequivalence study between two albendazole 400 mg tablets in healthy adult participants under fed conditions

Conditions: Intestinal Diseases

Summary: the goal of this study is to compare two formulations of albendazole of the same dose in healthy adult participants. researchers will compare the extent and rate to which the drug is absorbed.


Eligibility criteria:
inclusion criteria: 1. healthy, non-smoker, adult participants having body mass index (bmi) between 18.5 to 30.0 (both inclusive), calculated as weight in kilogram (kg)/ height in meter square (m2) 2. not having any significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead electrocardiogram (ecg) and x-ray chest (postero-anterior view) recordings. 3. able to understand and adhere to the study procedures 4. voluntary written informed consent is given for study participation 5. in case of female participants: surgically sterilized at least 6 months prior to study participation;or if of childbearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study, and serum pregnancy test must be negative. exclusion criteria: 1. known hypersensitivity or idiosyncratic reaction to albendazole or any excipients or any related drug or any substance. 2. history or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system. 3. any history or presence of asthma (including aspirin induced asthma) or nasal polyp or non-steroidal anti inflammatory drugs (nsaids) induced urticaria. 4. history or presence of seizure or psychiatric disorders. 5. ingestion of a medication (prescribed medication \& over the counter (otc) medication, herbal remedies, cimetidine, praziquantel, dexamethasone, ritonavir, phenytoin, carbamazepine, phenobarbital) at any time in 14 days prior to dosing and any vaccine (including covid-19 vaccine) from 14 days prior to dosing. in any such case participant selection will be at the discretion of the principal investigator. 6. receipt of an intervention or participation in a drug research study within a period of 90 days prior to the first dose of study intervention \*\*. * if intervention is received within 90 days where there is no blood loss except safety lab testing, participant can be included considering 10 half-lives duration of intervention received. 7. a positive hepatitis screen including hepatitis b surface antigen and/or hepatitis c virus (hcv) antibodies. 8. a positive test result for hiv antibody (1 and/or 2). 9. the presence of clinically significant abnormal laboratory values during screening.

Keywords: albendazole bioequivalence
hypnosis for treating xerostomia following radiotherapy in head & neck cancer patients

Conditions: Xerostomia

Summary: xerostomia develops in all patients with head and neck cancer following radiotherapy. it consists one of the main side effects which affects quality of life. currently, there is no standard of care for treating this condition. parasympathomimetic drugs may help but carry significant side effects. hypnosis may affect autonomic function such as salivation, in healthy people.in this study we will explore the efficacy of hypnosis in improving salivation, in the patient population.

10 head and neck cancer patients with xerostomia following radiotherapy will be assessed for severity of xerostomia using questionnares and quantitative salivation tests. patients responsive to citric acid will receive a hypnotic session with specific suggestion for salivation. saliva volume will be assessed pre and post hypnosis. patients will receive a cd with recorded hypnotic session to use freely at home. xerostomia will be assessed using a questionnare one week following hypnosis.

Eligibility criteria:
inclusion criteria: * radiotherapy for head and neck cancer * xerostomia exclusion criteria: * psychiatric illness (present or past)

Keywords: xerostomia hypnosis dry mouth radiotherapy head and neck cancer
usability of a novel cueing device for patients with parkinson's disease

Conditions: Freezing of Gait; Parkinson Disease

Summary: hypokinetic gait disorder and freezing of gait (fog) are frequent symptoms in the advanced stage of parkinson's disease (pd). these impair quality of life and significantly increase the risk of falls. external movement pacemakers have been developed to improve gait and avert fog by cueing strategies. the investigators developed a smart, small and lightweight, easy-to-handle wearable tactile cueing device (tcd), consisting of a control unit, two pulse generators and a battery-driven power supply. the device is programmed via a graphical user interface (gui).


Eligibility criteria:
inclusion criteria: * include patients who suffer from advanced pd. characteristic symptoms of parkinsonian gait like hypokinetic movements and/or fog have to be present. * parkinsonian gait is measured by the following items of the movement disorder society unified parkinson disease rating scale (mds-updrs): item 2.12, item 2.13, item 3.10 and item 3.11. the hoehn and yahr (hy) stage during on is 1-4/5. * moca ≥ 22/30. * participant has signed the informed consent. exclusion criteria: * inability of the participant to understand the ic or to follow the procedures of the study (as judged by the qualified physician). * significantly, impaired cognitive skills render the participant unable to use the tcd. * presence of severe motor fluctuations and severely impaired walking ability as defined by hy stage v during on. * clinically relevant skin lesions on the wrist or fixation points (usually the thighs).
eeg/mecg/emg evaluating the severity of aortic stenosis, heart failure and ischemic stroke through an artificial intelligenceassisted system.

Conditions: CVD

Summary: the specific objectives and methods of this project are: (1) to test the feasibility and accuracy of integrating eeg, mecg and emg for detecting the severity of diseases such as aortic stenosis, heart failure and ischemic stroke. (2) improve the accuracy of this multi-channel brain-heart-muscle device by using an artificial intelligence auxiliary system. (3) provide tailor-made interdisciplinary treatment strategies for patients with different disease states.


Eligibility criteria:
inclusion criteria 1. age≥20 year-old 2. healthy subjects or patients with a. metabolic syndrome (mets) ；b. hf with reduced ejection fractions (hfref, defined by left ventricular ejection fraction≤40%) and current or previous symptoms of hf；c. severe aortic stenosis (defined aortic valve area \< 1.0 cm2 or mean pressure gradient ≥ 40 mmhg), preparing to receive transcatheter aortic valve replacement ；d. acute ischemic stroke and admitted to stroke intensive care unit (icu), within 24 hours after onset the criteria of mets includes: 1. abdominal obesity: waist circumference (for asians) ≥ 90 cm in men and ≥ 80 cm in women; 2. hyperglycemia: serum fasting glucose level ≥ 100 mg/dl, or receiving drug treatment for elevated blood sugar; 3. reduced high-density lipoprotein cholesterol (hdl-c): serum hdl-c \< 40 mg/dl in men and \< 50 mg/dl in women or on cholesterol drug treatment; 4. elevated triglycerides: serum triglyceride ≥ 150 mg/dl or on drug treatment of hypertriglyceridemia; 5. hypertension: systolic blood pressure ≥ 130 mmhg, diastolic blood pressure ≥ 85 mmhg, or on antihypertensive drug treatment. exclusion criteria: 1. under treatment for malignancy 2. currently receiving immunosuppressants 3. modified rankin scale (mrs) ≥2 prior to the stroke 4. symptomatic hf in patients with acute ischemic stroke 5. unable to perform neurocognitive function test 6. unable to evaluate the physical activity using questionnaire or 6-minute walk test 7. unable to cooperate with examinations using 3e combo machine.

Keywords: heart failure aortic stenosis ischemic stroke
multi-center, open-label, single-ascending dose study of safety and tolerability of tn-201 in adults with symptomatic mybpc3 mutation-associated hcm

Conditions: Hypertrophic Cardiomyopathy

Summary: this is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (pd) of tn-201 in adult patients with symptomatic hypertrophic cardiomyopathy (hcm) caused by mutations in the mybpc3 gene.

the study will consist of 2 escalating dose cohorts (groups). the study will enroll at least 6 and as many as 30 patients. all patients will receive active drug (tn-201 gene therapy). the study will follow patients for 5 years following a single dose of tn-201.

Eligibility criteria:
inclusion criteria: * mybpc3 mutation * hypertrophic cardiomyopathy (obstructive and nonobstructive) * left ventricular ejection fraction ≥45% * nyha functional class ii or iii symptoms * nt-probnp ≥160pg/ml exclusion criteria: * high aav9 neutralizing antibody titer

Keywords: hypertrophic cardiomyopathy (hcm) myosin binding protein c3 (mybpc3) nonobstructive hcm genetic hcm familial hcm adenoassociated virus (aav) gene therapy obstructive hcm nhcm ohcm
telehealth support to increase physical activity in rett syndrome

Conditions: Rett Syndrome

Summary: this study will recruit families with a daughter with rett syndrome living in either australia, denmark or israel, and thereafter deliver individually designed participation programs using telehealth strategies. we will evaluate the effectiveness of the programs on reducing sedentary behaviours, increasing physical activity and increasing quality of life.

this project will implement two intertwined strategies that will build the capacity of the carer, clinical and therapy communities to support physical activity in rett syndrome. individuals with rett syndrome experience difficulties with movement and this can make it difficult to participate in regular physical activity. individuals with rett syndrome need support to participate in physical activities and it is important to work with primary caregivers when developing strategies to support physical activity. we will conduct a clinical trial that tests the effectiveness of working with primary caregivers to develop strategies suitable to their lives that aim to increase participation in physical activity in the individual with rett syndrome whom they support. we will use a clinical trial design and work with primary caregivers using telehealth. we will test whether this approach decreases sedentary time and increases physical activity. we will also test if there are changes in the sleep, behaviour and quality of life. we aim to recruit 60 families for this study, 26 of whom will live in australia. data from the three sites will be pooled for a stronger analysis. we acknowledge that physical activity can be associated with a fall and therefore our program will be developed with the primary caregiver to be suitable for their lives and capacity to provide support. however, by practicing more activity, the individuals with rett syndrome could be stronger and risks of falling could be reduced. the risks for the individual with rett syndrome are therefore low. to let the rett syndrome community know our results, we will then develop an online resource documenting the physical activity program and the evidence available to support it, and this will be freely available to families, carers and therapists wherever they live in the world.

Eligibility criteria:
inclusion criteria: * genetically confirmed rett syndrome * able to stand (with or without assistance) * live in australia, denmark or israel exclusion criteria: * individuals who have had spinal fusion over the previous 12 months * individuals who have had lower extremity orthopaedic surgery over the previous 6 months

Keywords: sedentary behaviour physical activity quality of life telehealth
octavacolon cancer blood tests octavagold and octavasilver - blood tests for the help in diagnosis of colon cancer clinical study protocol

Conditions: Colon Cancer

Summary: the octavacolon tests are qualitative plasma tests that are indicated to people above 18 years of age suspected with colon abnormality. the blood tests will provide additional information to the doctor in the course of colon cancer diagnosis for both normal population and high risk population

the clinical objective of this study is to develop two antibody-based blood tests for additional information during colon cancer diagnosis - 1. highly specific (octavagold) - provides additional information to doctors during evaluation of normal population. 2. highly sensitive (octavasilver) - provides additional information to doctors during evaluation of high risk population. the study will be considered successful it can achieve at least one of the following sets of performances - 1. for the octavagold - 95% specificity with at least 50% sensitivity. 2. for the octavasilver - 95% sensitivity with at least 50% specificity. the biological objective of this study is to find the best set of antigens, that when combined with the appropriate algorithm will support each of the above clinical objectives

Eligibility criteria:
inclusion criteria: subjects 18 years or over. subjects scheduled for colonoscopy or surgery exclusion criteria: * subjects less than 18 years of age * previous or concurrent synchronous cancers other than previous malignancies of the colon and recovered melanoma * autoimmune disorders diagnosed subjects * hematological malignancies * subjects under active chemotherapy treatment or chemotherapy in the past 6 months * steroid treatment in the past 3 months * subject undergoing immunosuppressive treatments * subject with verified melanoma colon cancer * subject with verified sarcoma colon cancer

Keywords: colon cancer cancer associated auto antibodies colon cancer blood test